National Cheng Kung University (NCKU), Taiwan signed a MOU with ScinoPharm Taiwan Ltd. on Nov. 24th. The NCKU President, Academician Michael M.C. Lai, attended together with Prof. Chyi-Her Lin, the Dean of the College of Medicine, Prof. Pin-Wen Lin, the Superintendent of the NCKU Hospital, Prof. Ih-Jen Su, the Deputy Superintendents of the NCKU Hospital, Prof. Ming-Jer Tang, the Vice President of Academic Affairs, Prof. Jung-Chun Huang, the Associate Vice President for R&D, Prof. Yung-Nane Yang, the Associate Vice President for R&D and the Division Head of University Development, and Distinguished Professor Shu-Hui Chen from Institute of Bioinformatics.
Dr. Jo Shen, the President and CEO of ScinoPharm Taiwan, also attended together with Dr. Hardy W. Chan, the Executive Vice President & Chief Scientific Officer of ScinoPharm Taiwan and the President of ScinoPharm Biotech and ScinoPharm Kunshan, China, Dr. Kuo-Hsi Cheng, the Vice President for Operations, Ms. Jessie Wang, the Director of Human Resource and Public Relationship, Ms. Min-Ling Cheng, Corporate Development Project manger, and Ms. Sabrina Wu, the Corporate Communications Manager.
According to the MOU, NCKU and ScinoPharm, Taiwan, both agree to encourage and promote cooperation in developing novel therapeutic agents and enabling technologies, as well as building competitive advantage in the knowledge-based industries in the greater China region and other territories. Moreover, they will also facilitate the relevant training of team members which are needed for the projects through exchanges of personnel on a mutually beneficial basis, and will explore opportunities for cooperation in any other areas of mutual interests.
“This is a good start between NCKU and ScinoPharm Taiwan Ltd. I hope to establish the university-industry cooperation and make a big breakthrough on the development of biotechnology industry in the future, which is one of the key industries for the future as declared by the Executive Yuan,” said President Lai.